Aptuit And Chiesi Collaborate To Treat Idiopathic Pulmonary Fibrosis
Aptuit, LLC, a premier global drug discovery and development CRO, and Chiesi Farmaceutici (Chiesi), an international research-focused Healthcare Group, announced today that they have entered an agreement under which Aptuit will conduct an integrated Discovery Project aimed at providing innovative drugs to treat Idiopathic Pulmonary Fibrosis.
Both parties will contribute scientifically, with Aptuit providing integrated early Discovery capabilities, including Medicinal Chemistry and Pharmacology, as well as Drug Metabolism and Pharmacokinetics, in order to identify promising compounds for further pre-clinical development.
Dr. Jonathan Goldman, Chief Executive Officer, Aptuit, stated, “This project builds upon the existing relationship between Chiesi and Aptuit in the field of Respiratory Drug Discovery. We are delighted to be working with Chiesi to identify early stage compounds that we hope will ultimately progress into innovative treatments for patients with this debilitating disease”.
Dr. Mark Parry Billings, Corporate Drug Development Head, Chiesi Farmaceutici, commented, “We are very pleased to announce the partnership with Aptuit. We share a common culture of scientific excellence and commitment to quality research and development. This alliance will allow our Project to progress effectively to the identification of lead compounds with a novel mechanism of action, leveraging our joint expertise in Respiratory drug discovery”.
Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Existing 20-year-old Multiple Sclerosis Drug Effective Against Multi-resistant BacteriaNews
A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.READ MORE
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Pre-Diabetes Discovery Marks Step Towards Precision MedicineNews
Identification of three molecules that can be used to accurately assess pre-diabetes – a key predictor of conditions such as diabetes and high blood pressure – has brought precision medicine for humans a step closer.READ MORE
Comments | 1 ADD COMMENT
Ana Aitawa | Oct 03, 2017
The global idiopathic pulmonary fibrosis treatment market expected to reach US$ 3.5 billion by 2021, growing at CAGR 14.4% over the forecast period 2017-2021, owing to increasing drug prices and rapid approval of new treatments. Visit Idiopathic Pulmonary Fibrosis (IPF) Treatment Market by Treatment Type – Pharmacological Treatment (Pirfenidone (Esbriet), Nintedanib (Ofev), Generic Pirfenidone); Non-pharmacological Treatment (Oxygen Therapy, Pulmonary Rehabilitation, Mechanical Ventilation, Lung Transplantation, Other Non-Pharmacological Treatment); Patients by Disease Severity (Mild, Moderate, Severe); Drug Pipeline Analysis (AEOL-10150, Lebrikizumab, Tipelukast, Tralokinumab, FG-3019, Simtuzumab, BMS-986020, AF-219, SAR156597, BG00011, PRM-151, PBI-4050) at https://www.ihealthcareanalyst.com/report/idiopathic-pulmonary-fibrosis-treatment-market/